Model consisting of ultrasonographic and simple blood indexes accurately identify compensated hepatitis B cirrhosis

Chen, Yongpeng; Dai, Letian; Wang, Jinglin; Zhu, Yi; Feng, Xiaoyue; Hou, Jinlin

doi:10.1111/j.1440-1746.2008.05421.x

Cited by 24 publications

(18 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2.2 Platelet count of less than 100,000/mm3 excluding the other possible causes. 2.3 Serum albumin less than 3.5 g/dL, or prothrombin time (PT) prolonged or international normalized ratios (INR) > 1.3 (anticoagulants or thrombolytic drugs discontinued more than 7 days) [27, 28]. For pre-cirrhotic CLD cases, the CLD patients who fulfilled the above criteria for clinically diagnosis of cirrhosis were excluded.…”

Section: Methodsmentioning

confidence: 99%

Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma

et al. 2017

View full text Add to dashboard Cite

Golgi protein 73 (GP73) has been suggested as a serum marker for the diagnosis of hepatocellular carcinoma (HCC). However, this has been challenged in recent years. In the present study, we found that the serum GP73 increased in HCC patients with cirrhosis but not in those without cirrhosis. The receiver operating characteristic curve (ROC) analysis demonstrated that serum GP73 had poor performance for differentiating HCC patients from cirrhosis patients. In addition, the immunohistochemistry revealed that aberrant expression of GP73 was primarily observed in cirrhotic and tumor liver tissues from both cirrhosis and HCC patients, but rarely in non-cirrhotic liver tissues from HCC patients without cirrhosis. Moreover, serum Alpha-fetoprotein in HCC patients with cirrhosis decreased sharply after resection of tumor tissue, while the serum GP73 remained stable. These data indicated that the background of cirrhosis was related to the elevation of serum GP73 in HCC patients. In conclusion, serum GP73 is not a suitable diagnostic marker for HCC.

show abstract

Section: Methodsmentioning

confidence: 99%

Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…On the other hand, patients with persistently normal serum ALT levels may not accept to undergo liver biopsy even though such patients are at risk of progressing to advanced fibrosis or cirrhosis [4]. Sampling error and interobserver variability also hinder liver biopsy from being applied more widely [5].…”

Section: Introductionmentioning

confidence: 99%

Liver Stiffness Measurement-Based Scoring System for Significant Inflammation Related to Chronic Hepatitis B

Hong

Zhang²,

Chen³

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

ObjectivesLiver biopsy is indispensable because liver stiffness measurement alone cannot provide information on intrahepatic inflammation. However, the presence of fibrosis highly correlates with inflammation. We constructed a noninvasive model to determine significant inflammation in chronic hepatitis B patients by using liver stiffness measurement and serum markers.MethodsThe training set included chronic hepatitis B patients (n = 327), and the validation set included 106 patients; liver biopsies were performed, liver histology was scored, and serum markers were investigated. All patients underwent liver stiffness measurement.ResultsAn inflammation activity scoring system for significant inflammation was constructed. In the training set, the area under the curve, sensitivity, and specificity of the fibrosis-based activity score were 0.964, 91.9%, and 90.8% in the HBeAg(+) patients and 0.978, 85.0%, and 94.0% in the HBeAg(−) patients, respectively. In the validation set, the area under the curve, sensitivity, and specificity of the fibrosis-based activity score were 0.971, 90.5%, and 92.5% in the HBeAg(+) patients and 0.977, 95.2%, and 95.8% in the HBeAg(−) patients. The liver stiffness measurement-based activity score was comparable to that of the fibrosis-based activity score in both HBeAg(+) and HBeAg(−) patients for recognizing significant inflammation (G ≥3).ConclusionsSignificant inflammation can be accurately predicted by this novel method. The liver stiffness measurement-based scoring system can be used without the aid of computers and provides a noninvasive alternative for the prediction of chronic hepatitis B-related significant inflammation.

show abstract

“…These included hematology profile, alanine aminotransferase (ALT, normal range 0-40 IU/L), aspartate aminotransferase (AST, normal range 0-45 IU/L), albumin, bilirubin and prothrombin time. 19 Transient elastography scanning TE was performed by two operators (Q.Z. 8,11,15 Ultrasonography Ultrasonic examination and TE were performed on the same day after overnight fasting.…”

Section: Routine Laboratory Testsmentioning

confidence: 99%

Is transient elastography valuable for high‐risk esophageal varices prediction in patients with hepatitis‐B‐related cirrhosis?

Chen

Zhang

Dai

et al. 2012

J of Gastro and Hepatol

Self Cite

View full text Add to dashboard Cite

show abstract

Model consisting of ultrasonographic and simple blood indexes accurately identify compensated hepatitis B cirrhosis

Abstract: Oligonucleotide microarray of the PCR product permits a rapid and accurate screening of SNPs of 23S rRNA gene from H. pylori. It is now possible to apply this hybridization technology in clinical diagnosis and treatment.

Cited by 24 publications

References 29 publications

Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma

Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma

Liver Stiffness Measurement-Based Scoring System for Significant Inflammation Related to Chronic Hepatitis B

Is transient elastography valuable for high‐risk esophageal varices prediction in patients with hepatitis‐B‐related cirrhosis?

Contact Info

Product

Resources

About